Drug Profile

Blinatumomab - Amgen

Alternative Names: AMG-103; Blincyto; MEDI-538; MT-103

Latest Information Update: 05 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Micromet Inc
Developer Amgen; Astellas Pharma; BeOne Medicines; M. D. Anderson Cancer Center; Merck & Co; Micromet Inc; National Cancer Institute (USA); University of British Columbia; University of California, Davis
Class Antineoplastics; Antirheumatics; Bispecific antibodies; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Precursor cell lymphoblastic leukaemia-lymphoma; Mantle-cell lymphoma; B-cell prolymphocytic leukaemia; B-cell lymphoma; T-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Hairy cell leukaemia
New Molecular Entity Yes

Marketed Precursor B-cell lymphoblastic leukaemia-lymphoma
Phase II/III Non-Hodgkin's lymphoma
Phase II Diffuse large B cell lymphoma; Rheumatoid arthritis; Richter's syndrome; Systemic lupus erythematosus
No development reported Burkitt's lymphoma
Discontinued Chronic lymphocytic leukaemia

31 Oct 2025 Amgen plans a phase III trial for Precursor B-cell lymphoblastic leukaemia-lymphoma (First-line therapy, Combination therapy) in January 2026 (SC) (NCT07223190)
21 Aug 2025 Amgen plans a phase I/II trial for Precursor B-cell lymphoblastic leukaemia-lymphoma (In neonates, In infants, In children, Second-line therapy or greater) (SC) in November 2025 (NCT07134088)
16 Jul 2025 Phase-II clinical trials in Rheumatoid arthritis (Treatment-experienced) in United Kingdom, Spain, Portugal, Italy, Germany, France, Belgium, USA (SC) (NCT06570798) (Amgen pipeline, August 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com